Telephone risk-based eligibility assessment for low-dose CT lung cancer screening

Jennifer L Dickson [ORCID],[1] Helen Hall [ORCID],[1] Carolyn Horst,[1] Sophie Tisi,[1] Priyam Verghese,[1] Anne-Marie Mullin,[2] Jonathan Teague,[2] Laura Farrelly,[2] Vicky Bowyer,[3] Kylie Gyertson,[3] Fanta Bojang,[3] Claire Levermore,[3] Tania Anastasiadis,[4] Karen Sennett,[5] John McCabe,[1] Anand Devaraj,[6,7] Arjun Nair,[3] Neal Navani,[1,3] Matthew EJ Callister [ORCID],[8] Allan Hackshaw,[2] SUMMIT Consortium, Samantha L Quaife [ORCID],[9] Sam M Janes [ORCID][1,3]

For numbered affiliations see end of article.

Correspondence to
Dr Sam M Janes, Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK; s.janes@ucl.ac.uk

SLQ and SMJ are joint senior authors.

ABSTRACT

Eligibility for lung cancer screening (LCS) requires assessment of lung cancer risk, based on smoking history alongside demographic and medical factors. Reliance on individual face-to-face eligibility assessment risks inefficiency and costliness. The SUMMIT Study introduced a telephone-based lung cancer risk assessment to guide invitation to face-to-face LCS eligibility assessment, which significantly increased the proportion of face-to-face attendees eligible for LCS. However, levels of agreement between phone screener and in-person responses were lower in younger individuals and minority ethnic groups. Telephone-based risk assessment is an efficient way to optimise selection for LCS appointments but requires further iteration to ensure an equitable approach.

INTRODUCTION

Lung cancer screening (LCS) using low-dose CT (LDCT) reduces lung cancer mortality in high-risk populations.[1 2] Eligibility is determined by lung cancer risk calculations, comprising smoking history, demographic and medical factors. No comprehensive population-based system exists from which LCS eligibility can be determined, therefore necessitating individual risk assessment of all potentially eligible individuals. Up to 88% of adults approached based on age alone were ultimately ineligible for LCS.[2 3] More targeted strategies including primary-care recorded smoking status or telephone screening of exclusion criteria (eg, current cancer treatment) still find 25%–50% of individuals ineligible at in-person assessment,[4 5] resulting in unnecessary appointments and potential distress.[6]

To reduce this inefficiency, the SUMMIT study introduced a telephone-based eligibility assessment ('phone screener') between the invitation and appointment to estimate individual lung cancer risk, in a similar approach to the Yorkshire Lung Screening Trial.[7] This manuscript reports the feasibility and accuracy of the phone screener in the first 12 months of recruitment.

METHODS

The SUMMIT study is a prospective observational cohort study aiming to assess the implementation of LDCT for LCS in a high-risk population and to validate a multicancer early detection blood test. Study eligibility was assessed via a three-step process: primary care invitation, phone screener and face-to-face 'Lung Health Check' (LHC) (table 1). Potentially eligible individuals were invited by post from across north central and east London, with those meeting either US Preventive Services Task Force (USPSTF) 2014 criteria[8] or prostate, lung, colorectal, ovarian (PLCO)$_{m2012}$ 6-year lung cancer risk[9] ≥1.3% invited to undergo LCS as part of the study.

The initial phone screener (V.1) verified age and smoking status only; however, due to a high proportion of LHC attendees being ineligible for LCS, questions were expanded (V.2, conducted by National Health Service (NHS) band four staff), enabling estimation of USPSTF and PLCO$_{m2012}$ criteria (table 1). Eligible individuals were offered an LHC appointment at which NHS band five staff (blinded to phone screener responses) asked questions and measured height and weight to accurately assess USPSTF and PLCO$_{m2012}$ criteria (taken as the 'gold standard').

Analysis

The accuracy of phone screener-based estimation of eligibility was quantified by the proportion of responders subsequently eligible for LCS at LHC appointment. Levels of agreement for individual participant responses during phone screener and LHC (for specific questions and overall eligibility status) were compared with Cohen's Kappa (K) and interpreted as per Landis and Koch,[10] for all LHC attendees and within age and ethnicity groups.

RESULTS

Effectiveness of telephone-based eligibility estimation on efficient utilisation of LHC appointments

Between March 2019 and April 2020, 30 759 individuals responded to the LHC invitation. The first 3.6% (n=1111) completed phone screener V.1, the remaining 96.4% (n=29 648) completed V.2 (figure 1). Significantly fewer individuals were eligible for an LHC using V.2 compared with V.1, (56.1% vs 86.9%, p<0.001). This resulted in an increased proportion of LHC attendees being LCS eligible (60.3% V.1 vs 82.6% V.2, p<0.001).

Table 1 Three step eligibility assessment for the SUMMIT Study and comparison of data collected at phone screener versus Lung Health Check to calculate lung cancer risk

Primary care invitation	Phone-screener risk assessment	Face-to-face 'lung health check' eligibility assessment
Age 55–77 years Current smoker within past 20 years **Exclusion criteria:** Dementia register Housebound Palliative care register or metastatic cancer Refused research	Version 1: Verification of age and smoking status (smoker within last 20 years and more than 100 cigarettes in lifetime) Version 2: Estimate of **USPSTF 2014 criteria** (30 pack-years of smoking and if a former smoker, have quit in the past 15 years) and/or **PLCO$_{m2012}$** 6-year lung cancer risk ≥1.3%	Calculation of: USPSTF 2014 criteria (30 pack-years of smoking and if a former smoker, have quit in the past 15 years) and/or **PLCO$_{m2012}$** 6 year lung cancer risk ≥1.3%

Phone screener (V2) estimate lung cancer risk	LHC assessment of lung cancer risk
Categorical variables	**Categorical variables**
Smoked >100 cigarettes in lifetime	Smoked >100 cigarettes in lifetime
Age (from GP extraction)	Age (from GP extraction)
Smoking status (current vs former)	Smoking status (current vs former)
Ethnicity (PLCO groups)	Ethnicity (PLCO groups)
Highest level of education	Highest level of education
History of COPD	History of COPD
Personal history of cancer	Personal history of cancer
Family history of lung cancer	Family history of lung cancer
Continuous variables	**Continuous variables**
Smoking duration	Smoking duration
Smoking consumption (amount)	Smoking consumption (amount)
	Periods of smoking abstinence
Self-reported height and weight (BMI estimate)	Measurement of height and weight (BMI calculated)

BMI, body mass index; COPD, chronic obstructive pulmonary disease; GP, general practitioner; LHC, lung health check; PLCO, prostate lung colorectal ovarian; USPSTF, united states preventive services task force.

Figure 1 Comparison between version 1 (A) and version 2 (B) of the phone screener in refining the population eligible for LHC. LCS, lung cancer screening; LHC, lung health check.

Agreement between telephone screening and LHC assessments

For the 14 714 individuals who completed phone screener V.2 and attended an LHC, the level of agreement between eligibility assessments conducted by phone screener versus LHC was fair (K=0.441) for USPSTF criteria and moderate (K=0.346) for PLCO$_{m2012}$ criteria (table 2). Level of agreement between phone screener and LHC responses was substantial or 'almost perfect' for all categorical variables except educational status (K=0.347) (table 2). Statistically significant differences in mean pack-year history and body mass index were observed (table 2), but their magnitudes were unlikely to be clinically significant. The level of agreement for eligibility assessments was lowest in individuals from an Asian ethnic group and those aged 55–59 years and highest in the white ethnic group and those aged over 75 years (table 2).

DISCUSSION

We present the first reported data demonstrating the impact of a telephone-based lung cancer risk assessment tool on optimising

selection for LCS appointments. Introduction of the multifactor phone screener significantly increased the proportion of ineligible individuals identified, resulting in fewer face-to-face LHC appointments. Phone screener and LHC responses showed high levels of agreement for most eligibility questions. However, lower levels of agreement were seen for educational status in all individuals, and for overall eligibility criteria in younger and minority ethnic groups. Lower levels of agreement for USPSTF criteria (vs PLCO$_{m2012}$) are likely explained by the greater influence of smoking consumption on this score. Ambiguous responses regarding smoking consumption during the phone screener were interpreted to maximise lung cancer risk estimates, allowing opportunity for face-to-face eligibility assessment for individuals with borderline eligibility criteria, which may account for some of this variation. With approximately 4–6 weeks between phone screener and LHC, responses may legitimately change between these timepoints. We are unable to assess the impact of potential data entry errors, but a minority of individuals were excluded due to implausible values, highlighting the need for real-time data validation. Finally, periods of smoking abstinence were included in pack-year calculations at the LHC (reported by 62.7%) but not during the phone screener.

Blinding LHC staff to telephone screener responses allowed LHC responses to be evaluated independently. However, comparisons could only be drawn for those who both responded to the LHC invitation and were eligible during the phone screener, who may differ to non-responders and those who were found to be ineligible at phone screener. From this non-randomised study, it is not possible to ascertain if those considered ineligible by telephone screening were truly

Table 2 Agreement between the phone screener questions and LHC assessments of (A) individual questions/eligibility criteria for all responders and (B) eligibility criteria across age/ethnicity subgroups

(A) All responders (n=14 714)	Agreement between phone screener V2 and LHC
Categorical	**Level of agreement between phone screener and LHC (%, Kappa*)**
≥100 cigarettes in lifetime	99.9% (K=NA)
Current vs former smoker	94.4% (K=0.891, p<0.001)
Ethnic group †	95.8% (K=0.849, p<0.001)
Highest level of education achieved	53.4% (K=0.347, p<0.001)
Personal history of COPD	87.5% (K=0.692, p<0.001)
Personal cancer history	95.8% (K=0.816, p<0.001)
Family history lung cancer	91.1% (K=0.693, p<0.001)
USPSTF criteria	76.6% (K=0.441, p<0.001)
PLCO$_{m2012}$ eligibility	82.2% (K=0.346, p<0.001)
Continuous	**Mean difference (95% CI) between phone screener and LHC responses**
BMI‡	−1.16 kg/m^2 (−1.21 to −1.11)
Pack-year history§	2.87 pack-years (2.58 to 3.16)

(B) Agreement between phone screener V2 and LHC eligibility criteria across different age/ethnicity groups			
	n	**USPSTF criteria**	**PLCO$_{m2012}$ eligibility**
Age (from GP data extraction)			
55–59 years	3643	71.0%	72.1%
60–64 years	3727	76.3%	79.8%
65–69 years	3541	79.6%	86.3%
70–74 years	2718	79.5%	90.8%
75 years +	1041	81.2%	91.2%
Missing	44		
Ethnicity			
Asian	1343	69.2%	69.9%
Black	796	68.8%	75.9%
Mixed	356	73.3%	77.5%
Other	629	70.7%	76.6%
White	11 590	78.5%	84.6%

*Level of agreement according to K values defined[10] as 'slight' (0–0.2), 'fair' (0.21–0.4), 'moderate' (0.41–0.6), 'substantial' (0.61–0.8) or 'almost perfect' (0.81–1).
†Summarised as three-category variable (Asian, black or white). n=2,013 (13.7%) declined to answer during the phone screener. Responses were mandated at the LHC.
‡n=114 excluded due to implausible values (weight <30 kg or >200 kg; height <135 cm or 200 cm).
§n=103 excluded due to implausible values (>80 cigarettes per day or >280 grams of tobacco per week; smoking start age >smoking cessation age; smoking start or cessation age >current age; period of smoking abstinence >total smoking duration).
.BMI, body mass index; COPD, chronic obstructive pulmonary disease; LHC, lung health check; PLCO, prostate lung colorectal ovary; USPSTF, united states preventive services task force.

ineligible for LCS, and therefore the impact on the sensitivity of risk assessment, but this should be a small proportion.

Further research should investigate validated multilingual translations, cultural variations with acceptability and inclusion of diverse educational categories to ensure equitability and accuracy. Additionally, efficiency gains resulting from the phone screener are likely to impact cost-effectiveness, which requires further evaluation alongside wider patient satisfaction and any potential added benefits of LHC attendance for ineligible individuals including cardiovascular risk assessment, spirometry and smoking cessation.

Existing studies demonstrate targeted invitations followed by in-person LCS eligibility assessment lead to inefficient resource utilisation. The data presented here support telephone-based risk assessment as an efficient way to optimise selection for LCS appointments.

Author affiliations
[1]Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
[2]Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK
[3]University College London Hospitals NHS Foundation Trust, London, UK
[4]Tower Hamlets Clinical Commissioning Group, London, UK
[5]Killick Street Health Centre, London, UK
[6]Department of Radiology, Royal Brompton Hospital, London, UK
[7]National Heart and Lung Institute, Imperial College London, London, UK
[8]Department of Respiratory Medicine, Leeds Teaching Hospitals, Leeds, Yorkshire, UK
[9]Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary

University of London, London, UK

ORCID iDs
Jennifer L Dickson http://orcid.org/0000-0002-9333-8320
Helen Hall http://orcid.org/0000-0001-7305-8367
Matthew EJ Callister http://orcid.org/0000-0001-8157-0803
Samantha L Quaife http://orcid.org/0000-0002-4918-6382
Sam M Janes http://orcid.org/0000-0002-6634-5939

REFERENCES
1 Aberle DR, Adams AM, Berg CD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
2 de Koning HJ, van der Aalst CM, de Jong PA, *et al*. Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med* 2020;382:503–13.
3 Field JK, Duffy SW, Baldwin DR, *et al*. UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* 2016;71:161–70.
4 Crosbie PA, Balata H, Evison M, *et al*. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester. *Thorax* 2018;74:405–9.
5 Bartlett EC, Kemp SV, Ridge CA, *et al*. Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation. *Lung Cancer* 2020;148:12–19.
6 Kummer S, Waller J, Ruparel M, *et al*. Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the lung screen uptake trial (LSUT). *Thorax* 2020;75:1065–73.
7 Crosbie PA, Gabe R, Simmonds I, *et al*. Yorkshire lung screening trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. *BMJ Open* 2020;10:e037075.
8 Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. preventive services Task force recommendation statement. *Ann Intern Med* 2014;160:330–8.
9 Tammemägi MC, Church TR, Hocking WG, *et al*. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med* 2014;11:e1001764.
10 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *International Biometric Society* 1977;33:159–74 http://www.jstor.com/stable/2529310